Loading...Loading...European pharma giant AstraZeneca Plc’s AZN Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in numerous cases. Lawyers representing the plaintiffs argue that the vaccine resulted in side effects for a small number of families, including brain injuries and fatalities.AstraZeneca, while contesting the claims, has acknowledged in court documents that its vaccine can, in rare instances, cause Thrombosis with Thrombocytopenia Syndrome (TTS), a condition characterized by blood clots and low blood platelet counts. In the legal document submitted to the High Court in February, AstraZeneca said: “It is admitted that the AstraZeneca vaccine can, in very rare cases, cause TTS.

正在加载。。。正在加载。。。欧洲制药巨头阿斯利康公司（AstraZeneca Plc）与牛津大学（University of Oxford）合作开发的AZN新型冠状病毒疫苗面临集体诉讼，指控其疫苗在许多情况下导致死亡和重伤。原告的律师辩称，疫苗对少数家庭产生了副作用，包括脑损伤和死亡。阿斯利康在对这些说法提出质疑的同时，在法庭文件中承认，其疫苗在极少数情况下会导致血小板减少综合征（TTS）血栓形成，TTS是一种以血块和血小板计数低为特征的疾病。阿斯利康在2月份提交给高等法院的法律文件中表示：“人们承认，阿斯利康疫苗在极少数情况下会引起TTS。

The causal mechanism is not known.”This admission follows a year of legal battles and could potentially lead to significant payouts for victims and their families.However, AstraZeneca maintains that the causal mechanism behind TTS is not fully understood and that the condition can occur independently of its vaccine.Meanwhile, lawyers argue that the AstraZeneca-Oxford vaccine is defective and its efficacy has been overstated.

因果机制尚不清楚。”这一承认是在一年的法律斗争之后做出的，可能会为受害者及其家人带来巨额赔偿。然而，阿斯利康坚持认为，TTS背后的因果机制尚不完全清楚，这种情况可能独立于其疫苗而发生。与此同时，律师们辩称，阿斯利康牛津疫苗存在缺陷，其功效被夸大了。

They claim that the vaccine has caused a new illness known as vaccine-induced immune thrombocytopenia and thrombosis (VITT), a subset of TTS, although AstraZeneca disputes the terminology.AstraZeneca’s vaccine is no longer used in the UK, and under-40s are offered alternative jabs due to safety concerns. Fifty-one cases have been filed in the High Court by victims and their families seeking compensation valued at approximately £100 million.Read Next: COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs.Price Action: AZN shares are up 0..

他们声称，该疫苗引起了一种新的疾病，称为疫苗诱导的免疫性血小板减少症和血栓形成（VITT），这是TTS的一个子集，尽管阿斯利康对该术语提出了质疑。阿斯利康的疫苗不再在英国使用，出于安全考虑，40岁以下的人可以选择注射。受害者及其家人向高等法院提交了51起案件，要求赔偿约1亿英镑。接下来阅读：随着向常规计划的转变，新型冠状病毒肺炎疫苗全球倡议即将结束。价格走势：AZN股价上涨0。。